# PDUFA dates April 2025: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2025-04

> 108 FDA catalysts are dated in April 2025, including 15 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in April 2025?

PDUFA dates in April 2025: CoV2601 (NVAX) on April 1, 2025; Aldeyra Therapeutics, Inc. (ALDX) on April 2, 2025; reproxalap (ALDX) on April 2, 2025; AMGEN INC (AMGN) on April 3, 2025; Royalty Pharma plc (RPRX) on April 3, 2025; CABOMETYX® (cabozantinib, EXEL) on April 3, 2025; and 9 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2025-04)

Source: SEC Form 10-Q, accession 0001000694-25-000021, https://www.sec.gov/Archives/edgar/data/1000694/000100069425000021/nvax-20250331.htm (retrieved 2026-11-12). Last confirmed 2025-05-08. Cite: https://sec-api.dev/fda-calendar/2025-04#answer

## PDUFA dates in April 2025

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| April 1, 2025 | NOVAVAX INC | NVAX | CoV2601 |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000021/nvax-20250331.htm) |
| April 2, 2025 | Aldeyra Therapeutics, Inc. | ALDX |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1341235/000095017025071602/aldx-20250331.htm) |
| April 2, 2025 | Aldeyra Therapeutics, Inc. | ALDX | reproxalap | signs and symptoms of dry eye disease | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000121390024099333/ea0221568-8k_aldeyra.htm) |
| April 3, 2025 | AMGEN INC | AMGN |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000005/amgn-20241231earningsrelea.htm) |
| April 3, 2025 | Royalty Pharma plc | RPRX |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000119312525005038/d919433dex991.htm) |
| April 3, 2025 | EXELIXIS, INC. | EXEL | CABOMETYX® (cabozantinib) | with previously treated advanced NET | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000017/exel2024q42024exhibit991.htm) |
| April 10, 2025 | ARGENX SE | ARGX |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm) |
| April 10, 2025 | ARGENX SE | ARGX | VYVGART (efgartigimod) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm) |
| April 18, 2025 | REGENERON PHARMACEUTICALS, INC. | REGN | Dupixent (dupilumab) | and adolescents aged 12 years and older with chronic spontaneous urticaria | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm) |
| April 20, 2025 | REGENERON PHARMACEUTICALS, INC. | REGN |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm) |
| April 20, 2025 | REGENERON PHARMACEUTICALS, INC. | REGN | Eylea® (eylea) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-1.htm) |
| April 21, 2025 | BRISTOL MYERS SQUIBB CO | BMY |  |  | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/bmy-20241231.htm) |
| April 26, 2025 | Telix Pharmaceuticals Ltd | TLX | TLX101 |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000047/q1bizupdate.htm) |
| April 29, 2025 | ABEONA THERAPEUTICS INC. | ABEO | prademagene |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315224044514/ex99-1.htm) |
| April 29, 2025 | ABEONA THERAPEUTICS INC. | ABEO |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315225010981/ex99-1.htm) |

## All catalysts in April 2025

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 1, 2025 | [BBO-11818 trial start](https://sec-api.dev/pdufa/bbo-11818) | BBOT |  | completed | "On April 1, 2025, BBOT announced that the first patient was dosed with BBO-11818 in the ongoing Phase 1 KONQUER-101 trial (NCT06917079) for advanced solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1869105/000119312526093997/bbot-ex99_1.htm)) |
| April 1, 2025 | [Annamycin trial start](https://sec-api.dev/pdufa/annamycin) | MBRX | AML patients | completed | "On April 1, 2025, Moleculin Biotech, Inc. (the "Company"), issued a press release which announced the first patient has been dosed in its Phase 3 pivotal trial evaluating Annamycin in combination with Cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as "AnnAraC") for the treatment of AML patients who are refractory to or relapsed after induction therapy (R/R AML)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1659617/000143774925010364/mbrx20250331_8k.htm)) |
| April 1, 2025 | [CoV2601 NDA/BLA acceptance](https://sec-api.dev/pdufa/cov2601) | NVAX |  | completed | "In the U.S., we submitted a BLA for our prototype vaccine and NVX-CoV2601, and the U.S. FDA notified us that our BLA was accepted for review with a PDUFA date of April 1, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000021/nvax-20250331.htm)) |
| April 1, 2025 | [CoV2601 PDUFA date](https://sec-api.dev/pdufa/cov2601) | NVAX |  | scheduled | "In the U.S., we submitted a BLA for our prototype vaccine and NVX-CoV2601, and the U.S. FDA notified us that our BLA was accepted for review with a PDUFA date of April 1, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000021/nvax-20250331.htm)) |
| April 1, 2025 | [TuHURA Biosciences, Inc./NV earnings report](https://sec-api.dev/companies/hura/catalysts) | HURA |  | completed | "TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498382/000119312525069706/d888264dex991.htm)) |
| April 1, 2025 | [Levosimendan NDA/BLA acceptance](https://sec-api.dev/pdufa/levosimendan) | TNXP |  | completed | "2,782 shares is April 1, 2025; the termination date for Series C Warrants to purchase up to an aggregate of approximately 10,884 shares is the earlier of (i) April 1, 2026 and (ii) 10 trading days following notice by the Company to the Series C Warrant holders of the Company's public announcement of the FDA's acknowledgement and acceptance of the Company's NDA relating to TNX-102 SL in patients with" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1430306/000199937125011050/tnxp-10q_063025.htm)) |
| April 1, 2025 | [Aquestive Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed, positive | "The pediatric study in subjects from the ages of 7 to 17 (weight greater than or equal to 30 kgs) was completed with positive topline data reported on April 1, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000074/aqst-20260930.htm)) |
| April 1, 2025 | [Tovecimig topline data readout](https://sec-api.dev/pdufa/tovecimig) | CMPX | advanced BTC | completed, met | "On April 1, 2025, the Company announced statistically significant top-line data on the primary efficacy endpoint for COMPANION-002, the Company's ongoing Phase 2/3 randomized trial of tovecimig (formerly CTX-009) in combination with paclitaxel in patients with advanced BTC." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/f8k_040125.htm)) |
| April 2, 2025 | [Aldeyra Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/aldx/catalysts) | ALDX |  | delayed | "On November 18, 2024, we announced that the FDA had accepted for review the Resubmitted NDA and assigned a PDUFA date of April 2, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1341235/000095017025071602/aldx-20250331.htm)) |
| April 2, 2025 | [EDG-7500 topline data readout](https://sec-api.dev/pdufa/edg-7500) | EWTX |  | completed, positive | "On April 2, 2025, the Company announced positive top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive HCM." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1710072/000110465925030839/tm2510984d2_8k.htm)) |
| April 2, 2025 | [Reproxalap PDUFA date](https://sec-api.dev/pdufa/reproxalap) | ALDX | signs and symptoms of dry eye disease | completed, complete response letter | "Release") to announce the Extension Letter and that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's resubmitted New Drug Application (NDA) for reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease, and has assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000121390024099333/ea0221568-8k_aldeyra.htm)) |
| April 2, 2025 | [Vanrafia® (atrasentan) FDA approval](https://sec-api.dev/pdufa/atrasentan) | NVS |  | completed, approved | "Vanrafia \| atrasentan \| 4/02/2025 \| To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progressionDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| April 2, 2025 | [VivoSim Labs, INC. earnings report](https://sec-api.dev/companies/vivs/catalysts) | VIVS |  | completed | "San Diego, CA - April 2, 2025 - Organovo Holdings, Inc. (Nasdaq: ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today reported preliminary unaudited cash for the fiscal year ending March 31, 2025, and net cash utilization results for the fiscal fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1497253/000095017025048888/onvo-ex99_1.htm)) |
| April 2, 2025 | [Reproxalap complete response letter (CRL)](https://sec-api.dev/pdufa/reproxalap) | ALDX | dry eye disease | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA216442_20250402.pdf%22)) |
| April 3, 2025 | [AMGEN INC PDUFA date](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | scheduled | "•The FDA accepted the regulatory submission for the Phase 3 MITIGATE study under priority review with a Prescription Drug User Fee Act (PDUFA) action date of April 3, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000005/amgn-20241231earningsrelea.htm)) |
| April 3, 2025 | [Royalty Pharma plc PDUFA date](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | scheduled | "Cabometyx PDUFA date is April 3, 2025. 7." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000119312525005038/d919433dex991.htm)) |
| April 3, 2025 | [LIFECORE BIOMEDICAL, INC. \DE\ earnings report](https://sec-api.dev/companies/lfcr/catalysts) | LFCR |  | completed | "Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1005286/000100528625000052/lfcr-25q3xex991earningsrel.htm)) |
| April 3, 2025 | [CABOMETYX® (cabozantinib) PDUFA date](https://sec-api.dev/pdufa/cabozantinib) | EXEL | with previously treated advanced NET | completed, approved | "In January 2025, Exelixis announced its key priorities and anticipated milestones for 2025, including: the potential commercial launch of CABOMETYX for the treatment of patients with previously treated advanced NET following completion of the FDA's review of Exelixis' sNDA, which has a PDUFA action date of April 3, 2025; expansion of zanzalintinib's pivotal development program with six ongoing or planned pivotal trials, including two pivotal RCC studies with Merck and additional" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976725000017/exel2024q42024exhibit991.htm)) |
| April 3, 2025 | [Reproxalap NDA/BLA submission](https://sec-api.dev/pdufa/reproxalap) | ALDX | dry eye disease | completed | "On April 3, 2025, Aldeyra issued the Press Release to announce that it had received a Complete Response Letter ("2025 Complete Response Letter") from the U.S. Food & Drug Administration ("FDA") regarding the Company's resubmitted New Drug Application ("resubmitted NDA") for reproxalap, an investigational drug candidate, for the treatment of dry eye disease." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200d8k.htm)) |
| April 7, 2025 | [Cardiomyopathy interim data readout](https://sec-api.dev/pdufa/cardiomyopathy) | LXEO |  | completed, positive | "NEW YORK - April 7, 2025 (GLOBE NEWSWIRE) - Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced positive interim data across all dose cohorts of LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000095017025051345/lxeo-ex99_2.htm)) |
| April 7, 2025 | [IMCIVREE® (setmelanotide) topline data readout](https://sec-api.dev/pdufa/setmelanotide) | RYTM | acquired hypothalamic obesity | completed, positive | "BOSTON, April 7, 2025 - Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced positive topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the treatment of acquired hypothalamic obesity." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025004507/rytm-20250407xex99d1.htm)) |
| April 7, 2025 | [Amjevita (adalimumab-atto) label expansion decision](https://sec-api.dev/pdufa/adalimumab-atto) | AMGN |  | completed, approved | "BLA761024 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20250407, review_priority STANDARD; sponsor_name AMGEN INC; product AMJEVITA (ADALIMUMAB-ATTO)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761024%22)) |
| April 7, 2025 | [IMCIVREE® (setmelanotide) trial start](https://sec-api.dev/pdufa/setmelanotide) | RYTM |  | completed | "On April 7, 2025, Rhythm announced it dosed the first patients with Prader-Willi syndrome in a 26-week, open-label Phase 2 trial of setmelanotide." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025006602/rytm-20250507xex99d1.htm)) |
| April 7, 2025 | [Dextenza (dexamethasone) label expansion decision](https://sec-api.dev/pdufa/dexamethasone) | OCUL |  | completed, approved | "NDA208742 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20250407, review_priority STANDARD; sponsor_name OCULAR THERAPEUTIX; product DEXTENZA (DEXAMETHASONE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208742%22)) |
| April 7, 2025 | [Cyramza (ramucirumab) label expansion decision](https://sec-api.dev/pdufa/ramucirumab) | LLY |  | completed, approved | "BLA125477 SUPPL-49 (Efficacy): submission_status AP, submission_status_date 20250407, review_priority PRIORITY; sponsor_name ELI LILLY AND CO; product CYRAMZA (RAMUCIRUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125477%22)) |
| April 8, 2025 | [Nurix Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nrix/catalysts) | NRIX |  | completed | "Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1549595/000154959525000053/nrix-20250408xexx991.htm)) |
| April 8, 2025 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "Inc. announces preliminary FIRST quarter 2025 results and RAISES H1 2025 NET SALES GUIDANCE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390025029629/ea023738701ex99-1_cormedix.htm)) |
| April 8, 2025 | [Yervoy® (ipilimumab) label expansion decision](https://sec-api.dev/pdufa/ipilimumab) | BMY |  | completed, approved | "BLA125377 SUPPL-135 (Efficacy): submission_status AP, submission_status_date 20250408, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product YERVOY (IPILIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125377%22)) |
| April 8, 2025 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-132 (Efficacy): submission_status AP, submission_status_date 20250408, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| April 9, 2025 | [Investigator trial start](https://sec-api.dev/pdufa/investigator) | CNTX |  | completed | "PHILADELPHIA, PA, April 9, 2025 -- Context Therapeutics Inc. ("Context" or "Company") (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the first patient has been dosed in the Phase 1 clinical trial of CT-95, a mesothelin ("MSLN") x CD3 T cell engaging ("TCE") bispecific antibody designed to target mesothelin-expressing cancers." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842952/000184295225000037/a20250409-ctx95firstpatien.htm)) |
| April 10, 2025 | [ARGENX SE PDUFA date](https://sec-api.dev/companies/argx/catalysts) | ARGX |  | scheduled | "We filed for approval of the PFS for gMG and CIDP in the U.S. with a PDUFA Date of April 10, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm)) |
| April 10, 2025 | [Vyvgart (efgartigimod alfa) FDA approval](https://sec-api.dev/pdufa/efgartigimod-alfa) | ARGX |  | completed, approved | "Exhibit 99.1 argenx Announces FDA Approval of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000110465925033857/tm2511923d1_ex99-1.htm)) |
| April 10, 2025 | [VYVGART (efgartigimod) FDA approval](https://sec-api.dev/pdufa/efgartigimod) | ARGX |  | completed, approved | "SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) approved a new option for patients to self-inject VYVGART®" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000110465925033857/tm2511923d1_ex99-1.htm)) |
| April 10, 2025 | [VYVGART (efgartigimod) PDUFA date](https://sec-api.dev/pdufa/efgartigimod) | ARGX |  | completed, approved | "This vision has already started to take shape as we continue to innovate on the patient experience with our pre- filled syringe (VYVGART SC) (with an expected Prescription Drug User Fee Act target action date (PDUFA Date) of April 10, 2025) and the auto-injector approval expected in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm)) |
| April 10, 2025 | [DARZALEX (daratumumab) label expansion decision](https://sec-api.dev/pdufa/daratumumab) | JNJ |  | completed, approved | "BLA761036 SUPPL-54 (Efficacy): submission_status AP, submission_status_date 20250410, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product DARZALEX (DARATUMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761036%22)) |
| April 10, 2025 | [Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) label expansion decision](https://sec-api.dev/pdufa/efgartigimod-alfa-and-hyaluronidase-qvfc) | ARGX |  | completed, approved | "BLA761304 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20250410, review_priority STANDARD; sponsor_name ARGENX BV; product VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761304%22)) |
| April 10, 2025 | [LIVMARLI® (maralixibat) FDA approval](https://sec-api.dev/pdufa/maralixibat) | MIRM |  | completed, approved | "NDA219485 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250410, review_priority STANDARD; sponsor_name MIRUM; product LIVMARLI (MARALIXIBAT CHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219485%22)) |
| April 14, 2025 | [IXCHIQ (ixchiq) FDA approval](https://sec-api.dev/pdufa/ixchiq) | VALN |  | completed, approved | "5 Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ® - Valneva" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1836564/000162828025017969/valnevapr2025_04x16xwvc2025.htm)) |
| April 15, 2025 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "The amounts reported in this press release reflect the company's preliminary estimates based solely upon information available to it as of the date of this press release, and the amounts reported are not a comprehensive statement of its financial results or position as of March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611025000044/ibrx-20254158xkexhibit991.htm)) |
| April 15, 2025 | [ABVC BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/abvc/catalysts) | ABVC |  | completed | "ABVC BioPharma Announces 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1173313/000121390025032135/ea023837201ex99-1_abvcbio.htm)) |
| April 15, 2025 | [XYNGARI (DMT310) topline data readout](https://sec-api.dev/pdufa/dmt310) | DRMA |  | completed, met | "SAN DIEGO, CA, April 15, 2025 - Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that XYNGARI™ had a statistically significant difference from placebo on three efficacy endpoints as early as week 4, which occurred after just four treatments with XYNGARI™." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000165495425004265/drma_ex991.htm)) |
| April 15, 2025 | [SPRUCE BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/sprb/catalysts) | SPRB |  | completed | "Spruce Biosciences also reported financial results for the year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1683553/000095017025053944/sprb-ex99_1.htm)) |
| April 15, 2025 | [WELIREG® (belzutifan) label expansion decision](https://sec-api.dev/pdufa/belzutifan) | MRK |  | completed, approved | "NDA215383 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20250415, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product WELIREG (BELZUTIFAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215383%22)) |
| April 15, 2025 | [CLEER-001 interim data readout](https://sec-api.dev/pdufa/cleer-001) | RKTO | high unmet medical needs, today | completed, positive | "York, NY — April 15, 2025 — Hoth Therapeutics, Inc.(NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative therapies for patients with high unmet medical needs, today announced positive interim data from the open-label portion of its Phase 2a clinical trial, CLEER-001, evaluating HT-001 for the treatment of pruritus associated with skin toxicities caused by Epidermal Growth Factor Receptor (EGFR) inhibitors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711786/000121390025031763/ea0238201ex99-1_hoth.htm)) |
| April 16, 2025 | [ABBOTT LABORATORIES earnings report](https://sec-api.dev/companies/abt/catalysts) | ABT |  | completed | "Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1800/000162828025017924/abt-2025q1xexhibitx991.htm)) |
| April 16, 2025 | [Akari Therapeutics Plc earnings report](https://sec-api.dev/companies/aktx/catalysts) | AKTX |  | completed | "Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1541157/000095017025054484/aktx-ex99_1.htm)) |
| April 17, 2025 | [Medpace Holdings, Inc. earnings report](https://sec-api.dev/companies/medp/catalysts) | MEDP |  | completed | "Medpace Holdings, Inc. Reports First Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668397/000166839725000056/medp-20250421exx991.htm)) |
| April 17, 2025 | [Eliquis (apixaban) FDA approval](https://sec-api.dev/pdufa/apixaban) | BMY |  | completed, approved | "NDA220073 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250417, review_priority PRIORITY; sponsor_name BRISTOL; product ELIQUIS (APIXABAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220073%22)) |
| April 17, 2025 | [Eliquis (apixaban) label expansion decision](https://sec-api.dev/pdufa/apixaban) | BMY |  | completed, approved | "NDA202155 SUPPL-39 (Efficacy): submission_status AP, submission_status_date 20250417, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product ELIQUIS (APIXABAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202155%22)) |
| April 17, 2025 | [Dupixent (dupilumab) label expansion decision](https://sec-api.dev/pdufa/dupilumab) | REGN |  | completed, approved | "BLA761055 SUPPL-51 (Efficacy): submission_status AP, submission_status_date 20250417, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product DUPIXENT (DUPILUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761055%22)) |
| April 17, 2025 | [Camzyos® (mavacamten) label expansion decision](https://sec-api.dev/pdufa/mavacamten) | BMY |  | completed, approved | "NDA214998 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20250417, review_priority STANDARD; sponsor_name BRISTOL; product CAMZYOS (MAVACAMTEN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214998%22)) |
| April 18, 2025 | [Dupixent (dupilumab) PDUFA date](https://sec-api.dev/pdufa/dupilumab) | REGN | and adolescents aged 12 years and older with chronic spontaneous urticaria | completed, approved | "•The FDA accepted for review the resubmission of an sBLA for Dupixent to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment, with a target action date of April 18, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm)) |
| April 20, 2025 | [REGENERON PHARMACEUTICALS, INC. PDUFA date](https://sec-api.dev/companies/regn/catalysts) | REGN |  | scheduled | "FDA decision on sBLA with two-year data for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) (target action date of April 20, 2025)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/exhibit991q42024.htm)) |
| April 20, 2025 | [Eylea® (eylea) PDUFA date](https://sec-api.dev/pdufa/eylea) | REGN |  | completed, complete response letter | "Longer term data in wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) are under FDA review with a PDUFA date of April 20, 2025 to potentially extend dosing intervals for EYLEA HD up to every-24 weeks." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_ex99-1.htm)) |
| April 21, 2025 | [BRISTOL MYERS SQUIBB CO PDUFA date](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | scheduled | "The FDA assigned a PDUFA goal date of April 21, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/bmy-20241231.htm)) |
| April 21, 2025 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-174 (Efficacy): submission_status AP, submission_status_date 20250421, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| April 22, 2025 | [Tevimbra (tislelizumab-jsgr) label expansion decision](https://sec-api.dev/pdufa/tislelizumab-jsgr) | ONC |  | completed, approved | "BLA761232 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20250422, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761232%22)) |
| April 23, 2025 | [AUCATZYL (obecabtagene autoleucel) interim data readout](https://sec-api.dev/pdufa/obecabtagene-autoleucel) | AUTL |  | scheduled | "Autolus will present the initial data from this trial and development plans at its R&D event being held on April 23, 2025, and is targeting H2 2025 for the presentation of full data with longer term patient follow-up." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730463/000173046325000010/autlex-991pr200325.htm)) |
| April 23, 2025 | [Ivonescimab interim data readout](https://sec-api.dev/pdufa/ivonescimab) | SMMT |  | completed, met | "On April 23, 2025, our partner, Akeso, announced that the HARMONi-6 Phase III clinical trial met its primary endpoint of progression-free survival (PFS) at a prespecified interim analysis conducted by an Independent Data Monitoring Committee." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1599298/000159929825000088/a2025_prx0501xq12025earn.htm)) |
| April 23, 2025 | [Viking Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vktx/catalysts) | VKTX |  | completed | "Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000095017025057337/vktx-ex99_1.htm)) |
| April 23, 2025 | [Autolus Therapeutics plc interim data readout](https://sec-api.dev/companies/autl/catalysts) | AUTL |  | scheduled | "Autolus will present the initial data from this trial and development plans at its R&D event being held on April 23, 2025, and its are targeting the second half of 2025 for the presentation of full data with longer term follow-up." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1730463/000173046325000019/autl-20241231.htm)) |
| April 23, 2025 | [Foralumab trial start](https://sec-api.dev/pdufa/foralumab) | TLSA | non-active secondary progressive multiple sclerosis | completed | "TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723069/000121390025034332/ea023921901ex99-1_tiziana.htm)) |
| April 23, 2025 | [Rezolute, Inc. interim data readout](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | completed, positive | "On April 23, 2025, we announced a positive outcome from an interim analysis of the sunRIZE study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1509261/000155837025007582/rzlt-20250331x10q.htm)) |
| April 23, 2025 | [Eylea® (eylea) complete response letter (CRL)](https://sec-api.dev/pdufa/eylea) | REGN |  | completed, complete response letter | "•The FDA issued a Complete Response Letter (CRL) for the EYLEA HD pre-filled syringe on April 23, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm)) |
| April 23, 2025 | [IBRANCE® (palbociclib) label expansion decision](https://sec-api.dev/pdufa/palbociclib) | PFE |  | completed, approved | "NDA212436 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20250423, review_priority STANDARD; sponsor_name PFIZER; product IBRANCE (PALBOCICLIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212436%22)) |
| April 24, 2025 | [Yeztugo® (lenacapavir) NDA/BLA acceptance](https://sec-api.dev/pdufa/lenacapavir) | GILD |  | completed | "•Announced FDA accepted New Drug Application submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a PDUFA date of June 19, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209525000009/exhibit991earningspressrel.htm)) |
| April 24, 2025 | [GILEAD SCIENCES, INC. earnings report](https://sec-api.dev/companies/gild/catalysts) | GILD |  | completed | "GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209525000009/exhibit991earningspressrel.htm)) |
| April 24, 2025 | [Merck & Co., Inc. earnings report](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | completed | "RAHWAY, N.J., April 24, 2025 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465925038301/tm2512885d1_ex99-1.htm)) |
| April 24, 2025 | [Supernus, Inc. earnings report](https://sec-api.dev/companies/supn/catalysts) | SUPN |  | completed | "Indivior Announces Results for the First Quarter Ended March 31, 2025; FY 2025 Guidance Unchanged" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1625297/000119312525091736/d926381dex991.htm)) |
| April 24, 2025 | [BRISTOL MYERS SQUIBB CO earnings report](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | completed | "Bristol Myers Squibb Reports First Quarter Financial Results for 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/14272/000001427225000089/a2025q1ex991-filing.htm)) |
| April 25, 2025 | [Avibactam FDA approval](https://sec-api.dev/pdufa/avibactam) | ABBV | complicated intra-abdominal infections | completed, approved | "•AbbVie announced that the FDA approved Emblaveo (aztreonam and avibactam), as the first monobactam/β-lactamase inhibitor combination antibiotic therapy to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteria." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000026/abbv-20250331xexhibit991.htm)) |
| April 25, 2025 | [IRONWOOD PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/irwd/catalysts) | IRWD |  | completed | "Ironwood plans to report full first quarter 2025 results in early May." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1446847/000110465925039013/tm2513134d1_ex99-1.htm)) |
| April 25, 2025 | [AbbVie Inc. earnings report](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed | "AbbVie Reports First-Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000026/abbv-20250331xexhibit991.htm)) |
| April 25, 2025 | [GUB014295 NDA/BLA submission](https://sec-api.dev/pdufa/gub014295) | ABBV | moderate to severe glabellar lines | completed | "•AbbVie announced that it submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of trenibotulinumtoxinE (BoNT/E) for the treatment of moderate to severe glabellar lines." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000026/abbv-20250331xexhibit991.htm)) |
| April 25, 2025 | [Pixclara (floretyrosine f-18) complete response letter (CRL)](https://sec-api.dev/pdufa/floretyrosine-f-18) | TLX |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA218592_20250425.pdf%22)) |
| April 26, 2025 | [TLX101 PDUFA date](https://sec-api.dev/pdufa/tlx101) | TLX |  | completed, complete response letter | "The NDA for TLX101-CDx (Pixclara®15, 18F-floretyrosine or 18F-FET), Telix's brain cancer imaging candidate, continues to progress with a PDUFA goal date of 26 April 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000047/q1bizupdate.htm)) |
| April 27, 2025 | [TLX101 complete response letter (CRL)](https://sec-api.dev/pdufa/tlx101) | TLX |  | completed, complete response letter | "Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that it has received a Complete Response Letter (CRL) from the United States (U.S.) Food and Drug Administration (FDA) for its New Drug Application (NDA) for TLX101-CDx (Floretyrosine F18 or 18F-FET, Pixclara®1), an investigational agent for the imaging of glioma, a rare and life-threatening brain cancer." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000049/pixpr.htm)) |
| April 28, 2025 | [ABEONA THERAPEUTICS INC. FDA approval](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed, approved | "On April 28, 2025, the United States Food and Drug Administration ("FDA") approved our Biologics" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/318306/000149315225021723/form10-q.htm)) |
| April 28, 2025 | [SG-001 FDA approval](https://sec-api.dev/pdufa/sg-001) | ADMA |  | completed, approved | "On April 28, 2025, ADMA Biologics, Inc., a Delaware corporation (the "Company"), issued a press release announcing that it has received U.S. Food and Drug Administration ("FDA") approval of the Company's innovative production yield enhancement process." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1368514/000114036125015881/ef20048038_8k.htm)) |
| April 28, 2025 | [NDV-01 interim data readout](https://sec-api.dev/pdufa/ndv-01) | RLMD | non-muscle invasive bladder cancer | completed, positive | "On April 28, 2025, the Company announced positive initial data from the Phase 2 study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1553643/000121390025073073/ea0248747-10q_relmada.htm)) |
| April 28, 2025 | [KOMZIFTI (ziftomenib) trial start](https://sec-api.dev/pdufa/ziftomenib) | KURA | advanced GIST | completed | "On April 28, 2025, we announced that we dosed the first patients in a Phase 1 trial evaluating ziftomenib in combination with imatinib in patients with advanced GIST after imatinib failure, which we refer to as the KOMET-015 trial." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1422143/000119312525263589/kura-20250930.htm)) |
| April 28, 2025 | [ET-600 NDA/BLA submission](https://sec-api.dev/pdufa/et-600) | ETON | central diabetes insipidus | completed | "On April 28, 2025, the Company submitted an NDA to the FDA for ET-600, the Company's proprietary, patented oral solution of desmopressin under development for the treatment of central diabetes insipidus." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1710340/000143774925016475/eton20250331_10q.htm)) |
| April 28, 2025 | [NRC HEALTH earnings report](https://sec-api.dev/companies/nrc/catalysts) | NRC |  | completed | "NRC HEALTH ANNOUNCES FIRST QUARTER RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/70487/000143774925013363/ex_806194.htm)) |
| April 28, 2025 | [Senti Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/snti/catalysts) | SNTI |  | completed | "Announces certain preliminary first quarter 2025 financial results and provides pipeline update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000185427025000046/ex992_snti2025clinicaldata.htm)) |
| April 28, 2025 | [RINVOQ® (upadacitinib) label expansion decision](https://sec-api.dev/pdufa/upadacitinib) | ABBV |  | completed, approved | "NDA211675 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20250428, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22)) |
| April 29, 2025 | [Prademagene PDUFA date](https://sec-api.dev/pdufa/prademagene) | ABEO |  | completed, approved | "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315224044514/ex99-1.htm)) |
| April 29, 2025 | [ABEONA THERAPEUTICS INC. PDUFA date](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | scheduled | "FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315225010981/ex99-1.htm)) |
| April 29, 2025 | [REPLIGEN CORP earnings report](https://sec-api.dev/companies/rgen/catalysts) | RGEN |  | completed | "Repligen Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/730272/000095017025059569/rgen-ex99_1.htm)) |
| April 29, 2025 | [Ascendis Pharma A/S NDA/BLA acceptance](https://sec-api.dev/companies/asnd/catalysts) | ASND |  | completed | "In December, we announced the FDA accepted the sBLA for review and set a Prescription Drug User Fee Act (PDUFA) goal date of July 27, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312525103766/d75062dex992.htm)) |
| April 29, 2025 | [PSV359 trial start](https://sec-api.dev/pdufa/psv359) | CATX | solid tumors | completed | "On April 29, 2025, Perspective Therapeutics, Inc. issued a press release announcing that the first patient was dosed with [212Pb]PSV359 in a Phase 1/2a dose-finding trial to determine the safety and preliminary anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/728387/000095017025059557/catx-20250429.htm)) |
| April 29, 2025 | [Kiniksa Pharmaceuticals International, plc earnings report](https://sec-api.dev/companies/knsa/catalysts) | KNSA |  | completed | "Reports First Quarter 2025 Financial Results and Recent Portfolio Execution" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730430/000110465925040641/tm2513395d1_ex99-1.htm)) |
| April 29, 2025 | [Revlimid® (lenalidomide) label expansion decision](https://sec-api.dev/pdufa/lenalidomide) | PFE |  | completed, approved | "Announced the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for Adcetris in combination with lenalidomide and a rituximab product for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma, after two or more lines of systemic therapy who are not eligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or chimeric antigen receptor (CAR) T-cell therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800325000111/pfe-03302025xex99.htm)) |
| April 29, 2025 | [REGENERON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/regn/catalysts) | REGN |  | completed | "Tarrytown, New York (April 29, 2025) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm)) |
| April 29, 2025 | [Prademagene FDA approval](https://sec-api.dev/pdufa/prademagene) | ABEO | wounds in adult and pediatric patients with RDEB | completed, approved | "April 29, 2025 - Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000164117225006548/ex99-1.htm)) |
| April 29, 2025 | [PFIZER INC earnings report](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed | "Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800325000111/pfe-03302025xex99.htm)) |
| April 29, 2025 | [INCYTE CORP earnings report](https://sec-api.dev/companies/incy/catalysts) | INCY |  | completed | "Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879169/000087916925000053/incy-q12025xexx991.htm)) |
| April 29, 2025 | [Attruby (acoramidis) earnings report](https://sec-api.dev/pdufa/acoramidis) | BBIO |  | completed | "PALO ALTO, CA - April 29, 2025 - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided an update on the Company's revenue, commercial progress of Attruby, and key late-stage pipeline highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000095017025060085/bbio-ex99_1.htm)) |
| April 29, 2025 | [Xencor Inc interim data readout](https://sec-api.dev/companies/xncr/catalysts) | XNCR | cancer and autoimmune diseases, today | completed, positive | "PASADENA, Calif. -- Apr. 29, 2025 -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced positive interim results from its first-in-human study of XmAb942, a high-potency, extended half-life, investigational anti-TL1A antibody in clinical development for patients with inflammatory bowel disease (IBD), such as ulcerative colitis (UC) and Crohn's disease (CD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326732/000132673225000048/xncr-20250429xexx992.htm)) |
| April 29, 2025 | [ABEONA THERAPEUTICS INC. NDA/BLA acceptance](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | scheduled | "FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315224045338/ex99-1.htm)) |
| April 29, 2025 | [Imaavy (nipocalimab-aahu) FDA approval](https://sec-api.dev/pdufa/nipocalimab-aahu) | JNJ | To treat generalized myasthenia gravis | completed, approved | "Imaavy \| nipocalimab-aahu \| 4/29/2025 \| To treat generalized myasthenia gravisDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| April 30, 2025 | [DBV Technologies S.A. earnings report](https://sec-api.dev/companies/dbvt/catalysts) | DBVT |  | completed | "DBV Technologies Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1613780/000119312525107505/d947872dex991.htm)) |
| April 30, 2025 | [Larimar Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lrmr/catalysts) | LRMR |  | completed | "Larimar Therapeutics Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000095017025060563/lrmr-ex99_1.htm)) |
| April 30, 2025 | [Bausch Health Companies Inc. earnings report](https://sec-api.dev/companies/bhc/catalysts) | BHC |  | completed | "BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2025 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/885590/000088559025000018/ex991-q1x2025.htm)) |
| April 30, 2025 | [CMND-100 FDA approval](https://sec-api.dev/pdufa/cmnd-100) | CMND |  | completed, approved | "2024, the Company announced that it was granted approval by the Israeli Ministry of Health and by the FDA, respectively to initiate its first-in-human Phase I/IIa clinical trial with CMND-100 in patients suffering from AUD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1892500/000121390025053839/ea024453601ex99-2_clearmind.htm)) |
| April 30, 2025 | [ARVINAS, INC. earnings report](https://sec-api.dev/companies/arvn/catalysts) | ARVN |  | completed | "Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000081/arvn-20250331xexx991.htm)) |
| April 30, 2025 | [IONIS PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/ions/catalysts) | IONS |  | completed | "Ionis reports first quarter 2025 financial results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/874015/000114036125016562/ef20048172_ex99-1.htm)) |
| April 30, 2025 | [UNITED THERAPEUTICS Corp earnings report](https://sec-api.dev/companies/uthr/catalysts) | UTHR |  | completed | "United Therapeutics Corporation Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1082554/000108255425000024/uthrq12025-ex991.htm)) |
| April 30, 2025 | [OPKO HEALTH, INC. earnings report](https://sec-api.dev/companies/opk/catalysts) | OPK |  | completed | "OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/944809/000143774925013848/ex_808700.htm)) |

Other months: https://sec-api.dev/fda-calendar/2025-03 , https://sec-api.dev/fda-calendar/2025-05. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates April 2025: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2025-04

```bibtex
@misc{secapidev_fda_calendar_2025_04_20261116,
  title        = {PDUFA dates April 2025: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2025-04}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2025_04_20261116","title":"PDUFA dates April 2025: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2025-04","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
